Evidence map›Paper›PMID 32211093›Full record

ArticleInternational journal of clinical and experimental pathology2020

Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Juan Wu, Ying Liu, Yaling Ma, Rui Wang, Xiaokun Ji, Yan Zhang, Yun Du

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Juan WuDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Ying LiuDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Yaling MaDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Rui WangDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Xiaokun JiDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Yan ZhangDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Yun DuDept of Cytology, The Fourth Hospital of Hebei Medical University Jiankang Road 12, Shijiazhuang 050011, Hebei Province, China.
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality all over the world, particularly in China. Metastasis is the main factor resulting in the poor prognosis of patients with NSCLC. CXCR4 and EGFR have been widely studied due to their critical role in tumor metastasis, but it remains more elusive then the relationship between CXCR4 and EGFR. Studies have demonstrated that many tumors have been found the existence of the "cross-talk" between EGFR and CXCR4 signaling pathways. In this context, we explored the relationship between EGFR and CXCR4 signaling pathways in lung cancer invasion and metastasis by both

Indexed as

chemokine receptor 4epidermal growth factor receptorinvasionLung adenocarcinomaPI3K/AKT signaling pathway

Identifiers

PMID32211093
PMCPMC7061788
OpenAlexW3015446222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.